UTHR Stock Analysis: Buy, Sell, or Hold?
UTHR - United Therapeutics Corp
$586.97
64.14 (12.27%)
▲
5d:
+12.61%
30d:
+16.49%
90d:
+15.74%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 29, 2026
29d
Get Alerted When UTHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: UTHR is 7.8% above fair value ($544.25). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: UTHR is 7.8% above fair value ($544.25). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$836.51
Based on 9.4% avg growth
INTRINSIC VALUE TODAY
$519.41
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UTHR is currently trading at $586.97, which is considered extended relative to its 30-day fair value range of $490.25 to $544.25. The stock's valuation (Forward PE: 16.3) is in line with its historical norms (16.7). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This pessimistic expectation contrasts with the company's recent 24.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, UTHR is in a uptrend. Immediate support is located at $517.59, while resistance sits at $607.89. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: UTHR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $593.92 (+13.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, UTHR is in a uptrend. Immediate support is located at $517.59, while resistance sits at $607.89. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: UTHR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $593.92 (+13.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$490.25 -
$544.25
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
59.5%
Protect Your Profits
Holding UTHR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.8% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.3%)
- BULLISH: Trading below Wall St target ($593.92)
Fair Price Analysis
30-Day Fair Range
$490.25 -
$544.25
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$517.59
Resistance Level
$607.89
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.27
Wall Street Target
$593.92
(+13.6%)
Revenue Growth (YoY)
7.4%
Earnings Growth (YoY)
24.5%
Profit Margin
41.9%
Valuation Discount vs History
-0.9% cheaper
PE vs Historical
16.3 vs 16.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.9%
(market-implied from PE analysis)
1-Year Target
$518.12
(-1%)
2-Year Target
$513.46
(-2%)
3-Year Target
$508.84
(-3%)
3-Yr Target (if PE normalizes)
(PE: 16→17)
$522.27
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 14.7%)
$1087.35
(+108%)
Base:
(SPY PE: 16.3, Growth: 14.7%)
$789.81
(+51%)
Bear:
(PE: 13.8, Growth: 14.7%)
$671.34
(+28%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 18.81 | Current EPS (TTM): $27.87
Bull Case
$670.30
(+29%)
Analyst growth 16.2%, PE expands to 20.7
Base Case
$609.36
(+17%)
Market implied 16.2%, PE stable at 18.8
Bear Case
$356.51
(-32%)
Severe decline -20.0%, PE contracts to 16.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.3 to 16.7
Stabilization Target:
$536.63
(+2.6%)
PE Expansion Potential:
+2.6%
Share & Embed Analysis
Last updated: March 30, 2026 1:57 PM ET
Data refreshes hourly during market hours. Next update: 2:57 PM
Data refreshes hourly during market hours. Next update: 2:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UTHR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Martine A Rothblatt
SELL
9500 shares
2026-03-16
Martine A Rothblatt
SELL
516 shares
2026-03-16
Martine A Rothblatt
SELL
8984 shares
2026-03-12
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
Advanced UTHR Option Strategies
Professional options setups generated by AI based on today's UTHR price and gamma walls.
